| Drug Type Bispecific antibody | 
| Synonyms QL401 | 
| Target | 
| Action inhibitors | 
| Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Hematologic Neoplasms | Phase 1 | United States  | 10 Aug 2022 | |
| Solid tumor | Phase 1 | United States  | 10 Aug 2022 | 






